These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 25104109)

  • 41. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
    Beer TM; Armstrong AJ; Rathkopf D; Loriot Y; Sternberg CN; Higano CS; Iversen P; Evans CP; Kim CS; Kimura G; Miller K; Saad F; Bjartell AS; Borre M; Mulders P; Tammela TL; Parli T; Sari S; van Os S; Theeuwes A; Tombal B
    Eur Urol; 2017 Feb; 71(2):151-154. PubMed ID: 27477525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enzalutamide in European and North American men participating in the AFFIRM trial.
    Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
    BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Stenzl A; Szmulewitz RZ; Petrylak D; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Ivanescu C; Rosbrook B; Ramaswamy K; Ganguli A; Haas GP; Armstrong AJ
    Prostate; 2022 Sep; 82(13):1237-1247. PubMed ID: 35675470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients.
    Kim CS; Theeuwes A; Kwon DD; Choi YD; Chung BH; Lee HM; Lee KH; Lee SE
    Investig Clin Urol; 2016 May; 57(3):174-83. PubMed ID: 27195316
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
    Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
    Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
    Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H; Saito A
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
    Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary.
    Ning YM; Pierce W; Maher VE; Karuri S; Tang SH; Chiu HJ; Palmby T; Zirkelbach JF; Marathe D; Mehrotra N; Liu Q; Ghosh D; Cottrell CL; Leighton J; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2013 Nov; 19(22):6067-73. PubMed ID: 24141628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
    Poon DMC; Wong KCW; Chan TW; Law K; Chan K; Lee EKC; Lee C; Chan M;
    Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ;
    N Engl J Med; 2019 Jul; 381(2):121-131. PubMed ID: 31157964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
    Kimura G; Yonese J; Fukagai T; Kamba T; Nishimura K; Nozawa M; Mansbach H; Theeuwes A; Beer TM; Tombal B; Ueda T
    Int J Urol; 2016 May; 23(5):395-403. PubMed ID: 27018069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Re: Effect of Enzalutamide on Time to First Skeletal-Related Event, Pain, and Quality of Life in Men with Castration-Resistant Prostate Cancer: Results from the Randomised, Phase 3 AFFIRM Trial.
    Taneja SS
    J Urol; 2015 Aug; 194(2):392-3. PubMed ID: 26195363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.